Drug Approval | February 24, 2024
Orchid Pharma's 'Exblifep' receives USFDA approval
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
Azithromycin Tablets USP, 500 mg had annual sales of US $20 million in the United States
KRIVIDA TRIVUS detects the specific virus causing a respiratory infection.
Zidavi is recommended by the Infectious Disease Society of America
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
